Breaking News: The FDA approved a new amyloid-targeting therapy to treat adults with early symptomatic #AlzheimersDisease. Learn more: https://e.lilly/4bsaOPk
Sounds very promissing. Hopefully it does not backlash in Europe as adecanumab did. Lecanemab and donanemab have good chances to be approved by EMA this year. Good luck. Biomedicine is a rising star. There are realy curative Interventions comming up for so many formerly incurable conditions (cancers, autoimmune conditions and now even neurodegenerative diseases). Very exciting. In particular the regimen (once monthly, i.v.) is very tempting (Compliance) Of course there will be a need for a proper infrastructure, due to the application. How will the industry be Insolved here?
I strongly opposed this approval, proving that this, too, would fail, as did aducanumab. I published my findings to advise Eli Lilly on how to make it work. I hope they will notice and create a truly effective product. I show that binding with transferrin enhances the binding efficiency of amyloid beta and increases transcytosis more than 1000 times. Just create a scFv of donanemab and bind it to the transferrin protein. FDAEli Lilly and CompanyIan HenshawBiogen https://www.mdpi.com/1422-0067/25/12/6683
Kelly Marvin
2w
Cool Taunya!! I’m getting new neuropathy study with Eli Lilly!!
Exciting news for patients and their caregivers suffering with this horrible disease
PraanaTech
3w
This is the beginning of the end of suffering of millions! Now is the time for rapid and large-scale diagnoses to compliment these efforts and eliminate AD.
I have to say for such a large organisation as Lilly your customer service is appalling 2 faulty Munjaro pens both reported one collected by you in early May still no reply to my complaint just that is is with your investigating team really !!!how long exactly does it take to look and test a pen
Congratulations on the outstanding achievement!
OgmentO
3w
This FDA approval of this treatment is a breakthrough and will offer hope for millions of patients and their families.🤗
I'll only get excited when it's affordable. Everyone getting excited is likely someone who can afford the $700 per vial and $32k annual cost. If Medicare and other health providers fully cover this or cover 3/4 of this cost, then I will applaud.
Certified Coach I Experienced Talent Strategist and Group Facilitator I Pharma & Tech I Midwesterner I Mother
3wThis is fantastic news for patients and families. I hope doctors will diagnose mild cognitive impairment this earlier so that they have the benefit of taking this medication. It still goes vastly un/mis diagnosed and now with this medication there is so much more hope. The number of people living this with disease is truly alarming and will only grow. This is an excellent step in providing an alternative to the ‘wait and see’ approach.